BiotechTube
Personalis

Personalis

PSNL
United States

Personalis is transforming cancer management through its advanced genomic sequencing and analysis technologies. The company's core offerings include the NeXT Platform® for comprehensive tumor profiling and the NeXT Personal® assay for highly sensitive MRD detection. Personalis collaborates with leading pharmaceutical companies and research institutions to accelerate drug development and improve patient outcomes. As a publicly traded company, it operates at the intersection of diagnostics, data, and therapeutic development in precision oncology.

personalis.com

PSNL · Stock Price

USD 7.78+4.36 (+127.49%)
Market Cap: $851.7M

Historical price data

AI Company Overview

Personalis is transforming cancer management through its advanced genomic sequencing and analysis technologies. The company's core offerings include the NeXT Platform® for comprehensive tumor profiling and the NeXT Personal® assay for highly sensitive MRD detection. Personalis collaborates with leading pharmaceutical companies and research institutions to accelerate drug development and improve patient outcomes. As a publicly traded company, it operates at the intersection of diagnostics, data, and therapeutic development in precision oncology.

Oncology

Technology Platform

The NeXT Platform® is a comprehensive, ultra-sensitive genomic profiling system for cancer, featuring whole-exome sequencing and a tumor-informed approach for molecular residual disease (MRD) detection via its NeXT Personal® assay.

Opportunities

The rapid adoption of MRD testing in clinical oncology represents a multi-billion dollar growth opportunity.
Personalis can expand by securing broader insurance reimbursement, penetrating new tumor types, and leveraging its sensitive platform for early cancer detection research.
Growing partnerships with biopharma for clinical trials provide a stable revenue base.

Risk Factors

Intense competition from well-funded rivals like Natera and Guardant Health poses market share risks.
Achieving consistent insurance reimbursement is critical for clinical test adoption.
The company must successfully execute its commercial transition to a clinician-facing model while continuing to burn cash to fund growth.

Competitive Landscape

Personalis competes directly with Natera (Signatera) and Guardant Health in the tumor-informed MRD market, and with Foundation Medicine and Tempus in biopharma genomic services. Its key differentiation is the ultra-high sensitivity and whole-exome-informed approach of its NeXT Platform®, positioning it as a performance leader in detecting minimal residual disease.